KEY TAKEAWAYS
- The study aimed to estimate the global prevalence of GIM through a systematic review and meta-analysis.
- The results showed the global prevalence of GIM is high, requiring further investigation and attention.
Sara Soroorikia and the team aimed to estimate the global prevalence of gastric intestinal metaplasia (GIM), a precancerous lesion that raises the risk of gastric cancer. Although previous studies have assessed GIM prevalence, this systematic review and meta-analysis were conducted to provide a comprehensive estimate.
Researchers conducted a systematic review and meta-analysis following PRISMA guidelines from 1988 to 2022. They searched databases such as Embase, PubMed, Scopus, Web of Science (WOS), MagIran, SID, and Google Scholar using validated MeSH/Emtree keywords.
The inclusion criteria included observational studies, full-text availability, and studies reporting GIM prevalence. Heterogeneity between studies was evaluated using the I2 index. Due to high heterogeneity, a random-effects model was applied, and data were analyzed using Comprehensive Meta-Analysis (CMA) software.
The results demonstrated that out of 4,946 studies, 20 met the inclusion criteria, with a total sample size of 57,263. The global prevalence of GIM was 17.5% (95% CI: 14.6-20.8%). The highest prevalence was reported in the American continent at 18.6% (95% CI: 13.8-24.6%) and in patients with gastroesophageal reflux at 22.9% (95% CI: 9.9-44.6%).
The study concluded that the global prevalence of GIM is high and warrants further investigation. Increased focus from experts, officials, and health policymakers is necessary to address this issue.
This study did not receive any funding from funding agencies.
Source: https://pubmed.ncbi.nlm.nih.gov/39342409/
Soroorikia S, Kazeminia M, Qaderi K, et al. (2024). “Global prevalence of gastric intestinal metaplasia: a systematic review and meta-analysis.” Syst Rev. 2024;13(1):247. Published 2024 Sep 28. doi:10.1186/s13643-024-02633-x
